Breadcrumb

Oncology Pipeline Main Article

Daiichi Sankyo Oncology Pipeline in the United States

As of May 2016

These are investigational agents and are not approved by the FDA or any other worldwide regulatory agency as a treatment for any indication. Efficacy and safety have not been established. There is no guarantee that these investigational agents will become commercially available.

Compound Tumor Type Relevant
Pathway
Highest Phase of Development
Quizartinib (AC220)

Newly-Diagnosed AML

FLT3-ITD

Phase 3

Quizartinib (AC220) Relapsed/Refractory AML

FLT3-ITD

Phase 3

Pexidartinib (PLX3397)

TGCT (PVNS / GCT-TS)

CSF-1R

Phase 3

Tivantinib (ARQ 197)

HCC

MET

Phase 3

Pexidartinib (PLX3397)

Glioblastoma

CSF-1R

Phase 2

Pexidartinib (PLX3397)

Melanoma

CSF-1R, KIT

Phase 2

Patritumab (U3-1287) Breast Cancer HER3 Phase 2
Pexidartinib (PLX3397) [in combination with pembrolizumab] Melanoma, Solid Cancer

CSF-1R, KIT

Phase 1/2
DS-3032

Solid Cancer, Lymphoma

MDM2

Phase 1

DS-3032 Leukemia MDM2 Phase 1
PLX7486

Solid Cancer

FMS/Trk

Phase 1

DS-8895 Solid Cancer EPHA2 Phase 1
DS-8273

Solid Cancer

DR5

Phase 1

PLX8394

Solid Cancer, Leukemia

BRAF

Phase 1

DS-6051

Solid Cancer

NTRK/ROS1

Phase 1

PLX9486 Solid Cancer KIT Phase 1
PLX73086 TGCT CSR-1R Phase 1
PLX51107 Hematologic Malignancies BRD4 Phase 1

 

daiichi-sankyo-oncology-pipeline-in-the-united-states-QuickLink

More Stories

Phase 3 Oncology Compounds

Daiichi Sankyo currently has three compounds in phase 3 clinical development with unique mechanisms of action...

read more ...